Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

CAPS Rating: 2 out of 5

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

Recs

0
Player Avatar pchop123 (76.57) Submitted: 7/25/2012 4:52:00 PM : Underperform Start Price: $18.98 ALNY Score: +8.48

Too much of a recent POP in Price to be justified based on their current situation

Featured Broker Partners


Advertisement